II participates m the neural regulation of the heart and clrculatlon at both central and penpheral sites To explore the role of endogenous angotensm II m blood pressure regulation, we conducted a randomized double-bhnd crossover trial m nme young healthy men (aged 33+3 [mean&SE] years) studied m the absence of salt restriction, comparing the effect of 1 week treatment with the anglotensm II receptor antagonist losartan (100 mg dally) against placebo with respect to the following variables, recorded during supme rest mtra-arterial blood pressure (BP), heart rate (HR), forearm vascular resistance and norepmephrme appearance rate, total body norepmephnne spillover, varlablhty of BP and HR (spectral analysis), and baroreflex sensltlvlty for HR (gain of the transfer function from systolic BP to HR) Blood pressure was 119+7/66+4 mm Hg (systolic BP/dlastohc BP) after 1 week of placebo and 112?6/61?3 mm Hg after 1 week of losartan (P-C 05) F orearm vascular resistance tended to fall, from 42 3+6 9 U on placebo to 32 8+5 0 U with losartan treatment (P= 07) Losartan had no effect on HR (6023 on placebo versus 59+2 beats per mmute with losartan), total body norepmephnne spillover (3 020.8 versus 3 3+1 2 nmol/mm), forearm norepmephnne appearance rate (3 8t 1 1 versus 5 321 1 pmol/lOO mL forearm tissue per minute), power m the high-or low-frequency components of the HR vanablhty and BP vanability spectra or on baroreflex sensitivity for HR Endogenous angotensm II contributes to the maintenance of supme BP m normal subJects, studied m the absence of sodium restnctlon
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The fall m BP caused by losartan 1s accompanied by a resetting of the baroreflex regulation of HR and sympathetic outflow, but baroreflex senntlvlty for heart rate IS not altered Therefore, the reduction m BP observed after short-term angotensm type 1 receptor antagonism may be achieved through a direct effect on vascular tone rather than through a primary reduction m sympathetic outflow (Hypertension. 1998; 31[part 2]:378-383.) Key Words: baroreceptor reflexes w blood pressure w heart rate varlablhty n humans w losartan n norepmephme kmetlcs n sympathetic nervous system A nglotensm II can modulate the neural regulation of the clrculatlon at both central and penpheral sites,' but its role m the control of BP in normotensive subjects remains a subject of debate Attenuation of anglotensm II formation by convertmg enzyme and rerun inhibitors lowers the BP of patients with essential hypertension, but not of normotenslve volunteers studied m the absence of salt restnctlon 2-5
The development of AT, receptor antagonists now provides a direct method of defimng the role of angotensm II m the regulation of normal BP These drugs also lower the BP of patients with essential hypertenslon,6 but m normotenslve volunteers, this action has been demonstrated only m the setting of renm-angotensm system actlvatlon '-" These observatlons again suggest that anglotensm II may not be involved m BP regulation m healthy subjects m the absence of salt and/or fluid restriction However, many of these stu&es m normotenslve volunteers used smgle or low doses of antagonists or measured BP nonmvaslvely These llmltatlons make mterpretatlon of any negative observations rather d&cult Therefore, we conducted a double-blind, placebo-controlled crossover trial m normotenslve volunteers studied without salt restnctlon to determme the effects of l-week treatment with the angotensm II AT, receptor antagonist losartan on BP, HR, and FBF To explore the possible modulation of the autonomic nervous system by endogenous angotensm II, we quantified forearm and total body NE appearance rate using a radiotracer Inc) I3 During measurement of FBF and blood samphng, clrculatlon to the hand was occluded by mflatlon of a wnst cuff to suprasystohc pressures to exclude, as much as possible, the cutaneous vascular bed f?om the experimental preparanon,'3 and the upper arm cuff was milated cychcally to a venous occlusion pressure of 40 mm Hg for 6 to 10 seconds Two houn afcer oral drug intake and at least 30 mmutes after these cannulahons, venous blood was sampled for the measurement of plasma renm activity and hematocnt and tntlated NE (Iwo-[nng-2,5,6-3H]NE, specific achvity of 30 to 60 Cl/mtnol) was mt&sed (1 @/mm) into a superfictal vem of the calf or foot Fifteen mmutes later, the wrist cuff was inflated to 200 mm Hg FBF was measured dunng the fint 5 minutes of i&hon Forearm venous and artenal blood sample9 were then sampled for plasma NE and [3H]NE, afier which the wnst cuffwas deflated and the rH]NE m!iiulon was stopped Intra-arterial BP was recorded for another 15 mmutes for subsequent spectral analysis of the HP. and BP signals and to calculate baroreceptor reflex sensltlvlty for HR from these values (see below) To avoid any potenhal effects of the mtra-artenal cannulatlon and local anesthehc on the determmatlon of forearm NE kmehcs and FBF, venous blood and FBF measurements were acqmred t?om the dommant arm, whereas artenal blood was sampled from the nondommant arm
Analytical Methods
Blood;amPles for analysis of plasma NE were collected m prechllled tubes contammg EDTA as an anticoagulant The tubes were centnfuged at 4"C, and the plasma was separated and stored at -7O'C Mean artenal pressure before the first dose of losartan was 4.9 mm Hg higher than on the correspondmg placebo day m the SIX subjects who received placebo first, and 4 1 mm Hg higher m the three who received losartan first Baseline HR was 5924 and 5823 beats per mmute before placebo and losartan respectively (NS) When expressed as changes from baseline and compared against placebo, there was a small but slgmficant reduction m both SBP and DBP and a higher HR after ingestion of losartan (PC 05 for all vanables, see feedback of angotensm II on remn release and mdlcatmg that the drug was effectively absorbed m all subjects The low plasma remn activity durmg placebo treatment confirms that these volunteers were not salt-restricted After 1 week losartan reduced BP slgmficantly, by approximately 5 to 7 mm Hg, but had no effect on HR (see Table 1 ) Losartan had no effect on artenal NE concentrations (1 2fO 3 versus 1.1 +O 4 nmol/L on the placebo day; NS), or on total body NE splllover (3 020 8 versus 3 3+1 0 nmol/mm, NS)
Oxygen saturation m deep antecubltal venous blood was 50 726 9% m subJects receiving placebo and 54 6+8 4% with losartan (NS), Indicating that the relative contnbutlon of venous blood ongmatmg from skm and muscle did not differ between the two study days Forearm vascular resistance tended to fall from 42 326 9 U on the placebo day, to 32 8+5 0 U on the losartan day (P= 07) Forearm NE appearance rate was not affected slgmficantly by losartan 3 8+1 1 versus 5.321 1 pmoU100 mL forearm tissue per minute on the placebo and losartan days, respectively (P= 14) One subject was excluded from power spectrum analysis because of frequently occurrmg extrasystoles, which precluded the selection of a stable recording penod of sufficient duration Losartan had no effect on the vanablhty of HR or BP m the remaining eight subJects (Table 2 ) Gains of the transfer functions between the BP and HR spectra were also similar on the placebo and losartan days ( 
Discussion
The purpose of this study was to determine whether endogenous anglotensm II parnclpates m the maintenance of supme BP m healthy young men Our objectives were, first, to determine the effect of angotensm II AT, receptor blockade on the BP of healthy volunteers studied without dietary salt restnctlon and, second, to determme whether any change m BP was accompamed by alterations m the neural regulation of the heart or peripheral clrculatlon or of forearm vascular tone The radlotracer technique, which permits simultaneous estlmatlon of forearm and total body NE release, was used to quantify the sympathoneural action of losartan When compared with placebo, the first dose of losartan caused a modest but slgmficant reduction m SBP and DBP and a significant, presumably baroreflex-mediated, increase m HR In contrast, after 1 week of losartan, slgmficant reducnons m SBP and DBP of greater magnitude were not accompanied by any detectable changes m HR, total body splllover, or forearm NE appearance rate within this sample size of nine subjects These findmgs mdlcate first that endogenous anglotensm II contributes to the maintenance of supme BP m normal subjects, studied m the absence of sodium restnctlon and second that losartan reset the arterial baroreflex regulation of HR and sympathetic outflow to the lower prevallmg level of BP. This concept 1s supported by expenmental data ' Forearm NE appearance rate was not reduced by losartan (and indeed tended to rise), yet there was a trend toward lower forearm vascular resistance, mdlcatmg that the vasodllator action of losartan 1s not medlated by attenuation of NE release from sympathetic nerve endings
The gam of the transfer function relating BP to pulse interval as assessed by spectral analysis was unaltered, mdlcatmg that this resetting 1s not accompanied by any change m baroreflex sensitivity for HR The dlffermg HR responses on the 1st and 7th day suggest that such resettmg does not occur fully after the first dose of losartan This dlssoclatlon may be related to the time course over which orally admmlstered losartan or its active metabohte binds to angotensm AT, receptors at sites involved m cardiovascular regulation both within and outside the blood-brain barrier ") It could be argued that this aspect of our observations should be interpreted cautiously, because the true magnitude of mfferences between responses to the first dose of placebo and losartan may have been obscured by a carryover effect of losartan m a few subjects, as there was no fixed washout penod between the two parts of this study However, this would seem unlikely m that BP did not nse over time m placebo-treated patients (Fig) , the number of \ubJects m whom a carryover effect might be present was sm.111 (three of nine), the differences m baseline values on the placebo and losartan days were independent of the order m which these capsules were administered, and the half-life m healthy volunteers of losartan (1 3 to 2 2 hours) and its rapldly appeanng active metabohte (4 4 to 6 4 hours)'"" are substantially less than 24 hours Taken together, these observations indicate that the hypotenslve effect of ATI receptor blockade m healthy normotenslve subjects 1s medlated through a tome action on vascular tone m skeletal muscle and m other hemodynamlcally slgmflcant vascular beds, rather than a pnmary reduction m sympathetic tone. An effect of losartan on salt and water excretion m these salt-repleted subjects 1s unlikely "J' A reducuon m vascular tone may be achieved by blockade of AT, receptors on smooth-muscle cells that cause vasoconstnctlon, by antagonism of AT, receptors on endothehal cells that release constnctmg factors, such as endothehn-1, when stlmulated,22~23 or by mhlbltlon of anglotensm II-induced formatlon of vascular superoxide m the vascular wall 24 This could subsequently deactivate mtnc oxlde,25 a substance with a tonic vasodllator action 26 The latter posslblhty 1s supported by an animal study m which the coronary vasodllator effect of losartan could be partially blocked by the mtnc oxide synthase mhlbltor ptutro-L-argmlne-methyl ester *' This demonstration of a slgmficant effect of specific blockade of the rerun-anglotensm system on BP m healthy volunteers, studied m the absence of salt restnctlon, contrasts with previous studies of losartan m healthy volunteers, m which BP fell only when the remn-anglotensm system was activated by sodium depletion 7+'2 Several charactenstlcs of our expenment may account for this In contrast to previous groups,"' " we recorded BP mvaslvely, thereby reducing possible measurement errors We admmlstered 100 mg of losartan, a dose shown to mhlblt the forearm vasoconstnctor response to mtra-arterially infused angotensm II ' It 1s not known whether a 50-mg dose, as gven m previous studies," also abohshes this response to angotensin AT, receptors are present within the central nervous system, sympathetic ganglia, and sympathetic nerve endmgs ' Dependmg on the expenmental preparation and species studled, the central nervous system admmlstratlon of angotensm II ~111 increase sympathetic outflow and mhlblt vagal nerve firmg ' Apphcatlon of anglotensm II mto sympathetic ganglia increases the firing rate of postganghomc nerves,28 mfuslon of anglotensm II raises muscle sympathetic nerve activity m humans,'" and stimulation of prejunctional anglotension II receptors on sympathetic nerve endmgs faclhtates NE release '" Despite this ublqultous mvolvement of central and peripheral AT, receptors m the neural control of the heart and clrculatlon,' losartan had no effect on total body NE splllover, forearm NE release, or frequency domam estimates of parasympathetic and sympathetic neural modulation of smoatnal discharge (although longer recordmg penods may be needed to detect any potential effect of AT, receptor antagonism on the very-low-frequency components of HR and BP vanablhty) Nor was the gam of baroreflex sensltlvlty for HR, which reflects pnmanly the parasympathetic efferent limb of the arterial baroreflex, affected by this mterventlon On reviewing the literature on mteractlons between anglotensm II, the sympathetic nervous system, and baroreceptor reflexes m the regulation of BP, Reid1 concluded that these potential sympathoexcltatory actions do not contribute significantly to the pressor response to anglotensm II The overall lack of any impact of losartan on these neural variables m these healthy men studied supme under condltlons of routme unrestricted sodium intake may be related to their low plasma remn actlvlty, as documented on the placebo day The effects of endogenous anglotensm II on vascular tone may assume greater importance with respect to BP and HR regulation than anglotensm-autonomic nervous system mteractlons under condltlons, such a$ these, when the renm-anglotensm system, the sympathethetlc nervous system, or both are relatively quiescent, and arterial baroreflex regulation of HR 1s intact In contrast, mteractlons between endogenous anglotemm II and sympathetic and parasympathetic outflow are more readily observed m chsease states m which both the rerun-anglotensm and the adrenerglc nervous systems are activated, such as acclerated hypertenslor?
and congestive heart failure 3' The lack of HR response to a fall m BP after long-term treatment with anglotensm-converting enzyme mhlbltlon has been attributed to a decrease m baroreflex sensltlvlty, a resetting of the baroreceptor reflex control of HR, or a combmatlon of these two effects ' Our results would suggest that AT, receptor blockade resets the baroreflex control of HR without altering the gam of the relatlonshlp between changes m systolic BP and pulse interval
The prmclpal hmltatlon to this study 1s that we did not compare responses to losartan with those of a direct vasodllator, free of any modulatmg influence on autonomic outflow (eg, hydralazme), to determine whether the magnitude of the resetting of the baroreceptor control of HR and sympathetic nervous system actlvlty over time 1s more pronounced (and HR and noradrenerglc responses attenuated) when BP 1s lowered by means of AT, receptor blockade This study demonstrates that angotensm II receptor subtype 1 blockade can reduce BP m healthy young men, studied m the absence of sodium restrlctlon This observation indicates that anglotensm II contributes to the maintenance of supme BP m normal subjects This modest hypotenslve action occurred without changes m HR or total body NE splllover, suggesting that the artenal baroreflex may have reset with time to the lower prevailing level of BP In the absence of corresponding reductions m sympathetic outflow, such resetting cannot be considered the pnmary mechanism by which losartan exerts its hypotenslve action m healthy humans 
